高风险前列腺癌的大分割剂量递增放疗:前列腺癌研究-5的安全性分析,一项由魁北克泌尿生殖放射肿瘤学组领导的3期试验
2012年2月至2015年3月,329例高风险前列腺癌患者随机接受标准分割或大分割放疗,均联合长期雄激素剥夺治疗。大分割组急性1级及以上胃肠道事件较多(102 vs 83,P=0.016),但8周随访时无显著差异;24个月时大分割组2级及以上迟发性泌尿生殖毒性较低(HR 0.26,95%CI 0.07-0.94,P=0.037),迟发性胃肠道毒性无显著差异。作者认为大分割放疗耐受性良好,可考虑作为标准分割的替代方案。
要点
- 大分割组急性1级及以上胃肠道事件102例 vs 标准分割组83例(P=0.016),8周随访时无显著差异。
- 24个月时大分割组2级及以上迟发性泌尿生殖毒性3例 vs 标准分割组11例(HR 0.26,95%CI 0.07-0.94,P=0.037)。
- 24个月时2级及以上迟发性胃肠道毒性两组无显著差异(HR 1.32,95%CI 0.62-2.83,P=0.482)。
核心结论
- 这是首项仅纳入高风险前列腺癌患者、接受长期雄激素剥夺治疗和盆腔放疗的中等大分割剂量递增放疗研究。
- 尽管数据未按非劣效性分析,结果提示中等大分割放疗耐受性良好,2年时与标准分割放疗相似,可考虑作为标准分割的替代方案。
研究设计与样本
- 2012年2月至2015年3月,329例高风险前列腺癌患者随机接受标准分割或大分割放疗,均接受新辅助、同期和长期辅助雄激素剥夺治疗。
- 标准分割放疗:前列腺76 Gy,每次2 Gy;盆腔淋巴结46 Gy。
- 大分割放疗:前列腺同时剂量递增68 Gy,每次2.72 Gy;盆腔淋巴结45 Gy,每次1.8 Gy。
- 共同主要终点为6个月急性毒性和24个月迟发性毒性;原设计为非劣效性,绝对界值5%,因两组毒性低于预期,非劣效性分析被完全放弃。
主要发现
- 大分割组164例,标准分割组165例。
- 急性1级及以上胃肠道事件:大分割组102例 vs 标准分割组83例(P=0.016),8周随访时差异不再显著。
- 急性1级及以上泌尿生殖事件:大分割组105例 vs 标准分割组99例(P=0.3),无差异。
- 24个月2级及以上迟发性胃肠道不良事件:标准分割组12例 vs 大分割组15例(HR 1.32,95%CI 0.62-2.83,P=0.482)。
- 24个月2级及以上迟发性泌尿生殖毒性:标准分割组11例 vs 大分割组3例(HR 0.26,95%CI 0.07-0.94,P=0.037)。
临床怎么用
- 作者认为中等大分割放疗耐受性良好,2年时与标准分割放疗相似,可考虑作为标准分割的替代方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The low α\β ratio of 1.2 to 2 for prostate cancer (PCa) suggests high radiation-fraction sensitivity and predicts a therapeutic advantage of hypofractionated (HF) radiation therapy (RT). To date, no phase 3 randomized clinical trial has compared moderately HF RT with standard fractionation (SF) exclusively in high-risk PCa patients. We are reporting the safety of moderate HF RT in high-risk PCa in an initially noninferiority-designed phase 3 clinical trial. METHODS AND MATERIALS: From February 2012 to March 2015, 329 high-risk PCa patients were randomized to receive either SF or HF RT. All patients received neoadjuvant, concurrent, and long-term adjuvant androgen deprivation therapy. Standard fractionation RT consisted of 76 Gy in 2 Gy per fraction to the prostate, where 46 Gy was delivered to the pelvic lymph nodes. Hypofractionated RT included concomitant dose escalation of 68 Gy in 2.72 Gy per fraction to the prostate and 45 Gy in 1.8 Gy per fraction to the pelvic lymph nodes. The coprimary endpoints were acute and delayed toxicity at 6 and 24 months, respectively. The trial was originally designed as a noninferiority with a 5% absolute margin. Given the lower-than-expected toxicities in both arms, the noninferiority analysis was completely dropped. RESULTS: Of the 329 patients, 164 were randomized to the HF and 165 to the SF arms. In total, there were more grade 1 or worse acute gastrointestinal (GI) events in the HF arm, 102 versus 83 events in the HF and SF arm, respectively (P = .016). This did not remain significant at 8 weeks of follow-up. There were no differences in grade 1 or worse acute GU events in the 2 arms, 105 versus 99 events in the HF and SF arm, respectively (P = .3). At 24 months, 12 patients in the SF arm and 15 patients in the HF arm had grade 2 or worse delayed GI-related adverse events (hazard ratio, 1.32; 95% CI, 0.62-2.83; P = .482). There were 11 patients in the SF arm and 3 patients in the HF arm with grade 2 or higher delayed genitourinary (GU) toxicities (hazard ratio, 0.26; 95% CI, 0.07-0.94; P = .037). There were 3 grade 3 GI and one grade 3 GU delayed toxicities in the HF arm and 3 grade 3 GU and no grade 3 GI toxicities in the SF arm. No grade 4-toxicities were reported. CONCLUSIONS: This is the first study of moderate HF dose-escalated RT in exclusively high-risk patients with prostate cancer treated with long-term androgen deprivation therapy and pelvic RT. Although our data were not analyzed as a noninferiority, our results demonstrate that moderately HF RT is well-tolerated, similar to SF RT at 2 years, and could be considered an alternative to SF RT.
引用
- Niazi T, Nabid A, Malagon T, et al. Hypofractionated, Dose Escalation Radiation Therapy for High-Risk Prostate Cancer: The Safety Analysis of the Prostate Cancer Study-5, a Groupe de Radio-Oncologie Génito-Urinaire de Quebec Led Phase 3 Trial. Int J Radiat Oncol Biol Phys. 2023. PMID: 37224928. doi:10.1016/j.ijrobp.2023.05.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。